Discovery of a first-in-class orally available HBV cccDNA inhibitor

The persistence of covalently closed circular DNA (cccDNA) in infected hepatocytes is the major barrier preventing viral eradication with existing therapies in patients with chronic hepatitis B. Therapeutic agents that can eliminate cccDNA are urgently needed to achieve viral eradication and thus HB...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of hepatology 2023-04, Vol.78 (4), p.742-753
Hauptverfasser:	Wang, Li, Zhu, Qihui, Zhang, Jitao David, Zhang, Yaling, Ni, Xiaoju, Xiang, Kunlun, Jiang, Jiaxi, Li, Baocun, Yu, Youjun, Hu, Hui, Zhang, Meifang, Wu, Waikwong, Zeng, Jing, Yan, Zhipeng, Dai, Jieyu, Sun, Kai, Zhang, Xin, Chen, Dongdong, Feng, Song, Sach-Peltason, Lisa, Young, John A.T., Gao, Lu
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antiviral Agents - pharmacology Antiviral Agents - therapeutic use cccDNA DNA, Circular - therapeutic use DNA, Viral - genetics HBV Hepatitis B virus Hepatitis B, Chronic - drug therapy Humans inhibitor Mice Mice, SCID Virus Replication
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!